Zai Lab Stock (NASDAQ:ZLAB), Trade Ideas

Zai Lab

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

pharma lab worker ai

Biotech

Equities

Large Cap

News

Health Care

General

ZLAB

Bristol Myers Squibb shares update on Phase 3 YELLOWSTONE trial for Zeposia (ozanimod) in Crohn&#39;s disease. Primary endpoint not met, safety consistent. Also, positive Phase 3 results for Krazati (adagrasib) in KRASG12C-mutated NSCLC.

One Good, One Bad News For Bristol Myers Squibb&#39;s Marketed Drugs: Details

Asia

Small Cap

Markets

Key Takeaways:


	CEO Jason Yang has increased his CStone stake multiple times over the past 18 months to 4.79% of outstanding shares, signaling confidence in the company


Stock Disconnect Triggers Investor Exodus From CStone Pharma

Long Ideas

Penny Stocks

Pre-Market Outlook

Trading Ideas

BIOL

CNSP

GILD

REVB

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Are Preparing To Pump In February

Zai Lab Limited - American Depositary Shares

Zai Lab Ltd

<p>As you may have heard, cannabis consumption among older folks is on the rise. More specifically, seniors are one of the fastest-growing groups of <a href="https://www.benzinga.com/cannabis">cannabis users in the U.S. </a></p>
<p>As it turns out, many older adults have been consuming weed for decades and new ones are joining in on the fun. Cannabis consumption among our parents and grandparents has quadrupled in the past eight years.</p>
<p>Study after study suggests that older adults are using cannabis to remedy an array of conditions such as sleep issues, pain,&nbsp;inflammation and to activate their appetites. </p>
<p>But most consume because they still enjoy getting high.</p>
<p>"Sure, I sleep better with cannabis and topical creams alleviate my knee pain, but that's all new. I've been smoking pot for the past four decades and I see no reason to stop getting high," said Cynthia P who recently retired as an ER nurse in Ohio where recreational marijuana <a href="https://www.benzinga.com/markets/cannabis/23/11/35664155/ohio-legalizes-cannabis-and-overwhelmingly-approves-abortion-rights">became legal</a> last November.</p>
<p>Scientists and researchers are wisely becoming interested in this Baby Boomer demographic of 77 million, many of whom are healthy, economically stable and have no plans of checking out anytime soon, so they say.</p>
<p>One particular<a href="https://www.frontiersin.org/articles/10.3389/fnagi.2022.804890/full" target="_blank" rel="noreferrer noopener">&nbsp;study</a>,&nbsp;that examined marijuana use in adults aged&nbsp;60 to 88 found that&nbsp;whole-plant cannabis did&nbsp;not harm&nbsp;cognition but rather the opposite.&nbsp;Older cannabis users, relative to non-users, had&nbsp;significantly greater neuronal communication between the cerebellum and hippocampus.</p>
<p><strong>Why?</strong> Age-related changes in the&nbsp;<a href="https://www.benzinga.com/markets/cannabis/22/07/28272841/the-endocannabinoid-system-101-the-basics-made-easy" target="_blank" rel="noreferrer noopener">endocannabinoid system</a>&nbsp;(ECS) include a decrease in the number of cannabinoid receptors throughout the brain.&nbsp;The ECS,&nbsp;a significant aspect of our human physiology that&nbsp;helps maintain homeostasis,&nbsp;is a complex cell-signaling system in the brain and body that interacts with just about all of our&nbsp;other body systems.&nbsp;</p>
<p><strong>Which means? </strong>During normal aging, the decline in cannabinoid receptors correlates with increased levels of inflammation in these brain regions causing a loss of neurons in the hippocampus, which is critical for learning and&nbsp;memory.&nbsp;This, in short, explains age-related memory impairment.&nbsp;&nbsp;</p>
<p>"Oh, I believe that," Cynthia told Benzinga. "While I never consumed for a full shift before going to work, I'm convinced that marijuana has helped keep me and my mind sharp as I aged. I'm not saying it's for everyone, but for people of my generation there's nothing better."</p>
<p><em>Now Read: <a href="https://www.benzinga.com/markets/cannabis/24/04/38341776/hemp-space-grew-3x-the-rate-of-cannabis-where-did-marijuana-get-it-wrong">Hemp Space Grew 3X The Rate Of Cannabis, Where Did Marijuana Get It Wrong?</a></em></p>
<p><em>Photo: Shutterstock</em></p>


Cannabis

Exclusives

It's 4/20, Do You Know Where Your Parents Are?

<p>The Detroit Lions finished with one of their best records in years for the 2023 season, which means they will have a lower pick in the<a href="https://www.benzinga.com/nfldraft/"> 2024 NFL Draft.</a></p>
<p>Would General Manager<strong> Brad Holmes</strong> consider trading out of the first round with the 2024 NFL Draft taking place in Detroit?</p>
<p><strong>What Happened: </strong>Detroit Lions fans might not like the answer given by Holmes to the media on scenarios that could see the Lions trade their 29<sup>th</sup> overall first-round pick and move back in the <a href="https://www.benzinga.com/nfldraft/detroit-live-events/">2024 NFL Draft.</a></p>
<p>Holmes was asked about a scenario of trading out of the first round and didn't hesitate to say he will do what is best for the franchise.</p>
<p>"We have to do the right thing for the organization," Holmes said, as <a href="https://www.detroitlions.com/news/holmes-prepared-to-apologize-to-fans-if-lions-trade-out-of-first-round">reported </a>by Lions writer Mike O'Hara.</p>
<p>Holmes said while he would consider trading out of the first round, it's important to note that, with the draft taking place in Detroit, there might be a greater chance of upsetting the fans if he makes such a move.</p>
<p>A trade out of the first round could mean that any Lions fans in attendance Thursday will have spent all day downtown to watch other teams take their players in the draft.</p>
<p>Holmes said he would send out a "PSA and apologize" if he trades out of the first round.</p>
<p>"Hopefully, our fans will forgive us. We won't expect immediate forgiveness right then and there, but hopefully when the season starts."</p>
<p>Detroit was announced as the host city for the NFL Draft back in 2022.</p>
<p>"Another opportunity for our franchise and our city and just for the world to kind of migrate to downtown Detroit," Holmes said earlier this week.</p>
<p><em>Related Link: <a href="https://www.benzinga.com/general/sports-betting/24/04/38318190/michigan-wolverines-will-have-6-high-demand-players-in-2024-nfl-draft-will-history-repeat-">Michigan Wolverines Will Have 6 High-Demand Players In 2024 NFL Draft: Will History Repeat Itself?</a></em></p>
<p><strong>Why It's Important:</strong> Holmes is no stranger to trading in the NFL Draft. Since joining as the Lions GM in 2021, Holmes has taken part in several drafts for the team and is known for dealmaking.</p>
<p>This includes the 2023 NFL Draft, which saw the Lions trade their sixth overall pick, acquired from the Los Angeles Rams in the <strong>Matthew Stafford</strong> trade. The Lions traded the sixth pick to the Arizona Cardinals and received back the 12<sup>th</sup>, 34<sup>th</sup> and 168<sup>th</sup> overall picks.</p>
<p>Lions fans will remember the 2023 Draft saw several impact players taken including running back <strong>Jahymyr Gibbs </strong>with the 12<sup>th</sup> pick and tight end<strong> Sam LaPorta </strong>with the 34<sup>th</sup> pick. Both rookies played in the 2023 NFL season and were among the top first-year players, finishing third and fourth, respectively, in NFC offensive rookie of the year voting.</p>
<p>The 12-5 record and appearance in the NFC Championship game gives the Lions the 29<sup>th</sup> overall pick, one of their lowest earned in years.</p>
<p>The Lions also have the 61<sup>st</sup> overall pick and 73<sup>rd</sup>, but have only those three picks in the first four rounds, with no fourth-round pick this year. This could prompt Holmes to be open to trades to pick up additional picks. The Lions also have a fifth-round pick, two sixth-round picks and a seventh-round pick, for seven overall picks.</p>
<p>In the 2023 NFL Draft, the Lions had eight picks, including two first-round picks and two second-round picks.</p>
<p>The Lions have had a first round pick in every season since 1994, with 1993 being the last year they didn't select a player in the first round.</p>
<p>The Lions&#8217; top needs by position include cornerback, offensive line and wide receiver. The Lions last took a wide receiver in the first round of 2022 (<strong>Jameson Williams</strong>) and a cornerback in the first round of 2020 (<strong>Jeff Okudah</strong>). For the offensive line, the Lions last took a guard or center in the first round in 2018 with <strong>Frank Ragnow,</strong> and last took an offensive tackle in the first round in 2021 with <strong>Penei Sewell.</strong> Of these four players, three are still with the Lions.</p>
<p>Join Benzinga's live draft reaction show Thursday, April 25 to hear our instant thought on who the Lions take 29<sup>th</sup> overall or our reaction to the Lions trading out of the first round.</p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534; LIVE NFL Draft Watch Party: Benzinga&#039;s Expert Analysis &amp; Reactions!" width="500" height="281" src="https://www.youtube.com/embed/XMBqIWZb7h0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><em>Photo via Shutterstock. </em></p>


Sports

Detroit Lions Have First-Round Pick Every Year Since 1994: Would They Really Trade Out With Draft In Motor City?

<p>&quot;We are disappointed to announce the wind-down of our Phase 2 NASH trial, which we attribute entirely to resource constraints,&quot; said John Brancaccio, Executive Chairman of Hepion. &quot;The Company remains committed to its strategic alternative efforts previously announced in December 2023. Given the number of enrolled NASH patients to date and the low probability of generating relevant efficacy data to support a registrational trial with our current cash resources, we have opted to wind down the program and assure that patients are transitioned out of the trial in a safe and compliant manner. There were no safety concerns observed for rencofilstat in the ASCEND-NASH trial.&quot;</p>


HEPA

Hepion Pharmaceuticals Says Given The Number Of Enrolled NASH Patients To Date And The Low Probability Of Generating Relevant Efficacy Data To Support A Registrational Trial With Our Current Cash Resources, We Have Opted To Wind Down The Program And Assure That Patients Are Transitioned Out Of The Trial In A Safe And Compliant Manner"

Hepion Pharmaceuticals Shares Resumed Trading

<p>Sen.<strong> Elizabeth Warren</strong> (D-Mass.) voiced her support for a Department of Justice antitrust case against leading technology company <strong>Apple Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), which was <a href="https://www.benzinga.com/news/24/03/37905532/apple-slams-dangerous-doj-lawsuit-tim-cooks-iphone-suggestion-returns-to-haunt-and-potential-google">announced last month.</a></p>
<p>In comments shared on social media, Warren took aim at the smartphone market segment of Apple.</p>
<p><strong>What Happened:</strong> Apple is one of the largest smartphone companies in the world and in 2023 had seven of the top 10 selling smartphones globally <a href="https://www.benzinga.com/news/24/02/37245799/apple-dominates-2023-smartphone-list-with-7-of-top-10-models-why-its-important-for-iphone-growth">according to a report.</a></p>
<p>According to Warren, Apple has a monopoly in the smartphone market and one of the company's key features could be ruining friendships and relationships.</p>
<p>"Green texts on iPhones, they're ruining relationships," Warren <a href="https://twitter.com/SenWarren/status/1781086997014040759">said </a>in a video posted on X.</p>
<p>The green texts refer to the texts that come from non-Apple phones in green bubbles versus the blue bubbles displayed by iPhone users.</p>
<p>"Non iPhone users everywhere are being excluded from group texts."</p>
<p>Warren said that this means some non-Apple smartphone users are not being included in chats about vacation plans, group chats or chats with other sports fans.</p>
<p>"And who's to blame here? Apple."</p>
<p>Warren said that the green vs. blue bubble text icons are just one example of the dirty tactics used by Apple to "keep a stranglehold on the smartphone market."</p>
<p>"Apple has used its monopoly on the smartphone to lock Americans into services and amass billions of dollars in profits."</p>
<p>Warren mentioned that apps that would let Google users use iMessage and get blue texts were <a href="https://www.benzinga.com/news/23/12/36165068/apple-pulls-plug-on-imessage-for-android-app-beeper-mini-its-back-to-green-bubbles-now-for-android-u">blocked by Apple.</a></p>
<p>"It's time to break up Apple's monopoly now."</p>
<p><em>Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37876155/apple-doj-lawsuit-could-challenge-core-business-model-leading-analyst-predicts-what">Apple DOJ Lawsuit Could Challenge &#8216;Core Business Model&#8217;: Leading Analyst Predicts What&#8217;s Next For Tech Giant</a></em></p>
<p><strong>Why It's Important</strong>: The video shared by Warren was Community Noted on X, with readers providing more context.</p>
<p>"As of Jan 2024, iPhone has a 57% market share, to Android 42% in North America. A monopoly is exclusive control, or no close substitutes," the note reads.</p>
<p>In March, the Department of Justice filed an antitrust suit against Apple, which includes allegations that the company restricts access to iPhone hardware and software features.</p>
<p>A <a href="https://9to5mac.com/2024/04/19/elizabeth-warren-on-green-texts/">report </a>from 9to5Mac indicates that the antitrust lawsuit now encompasses claims from non-iPhone users who feel socially stigmatized and excluded in chats with iPhone users. This issue stems from the ongoing<a href="https://www.benzinga.com/news/23/09/34818276/get-the-message-google-roasts-apple-with-new-mocking-ipager-add-to-end-green-vs-blue-text-bubbles-wa"> blue vs. green bubble text debate.</a></p>
<p><strong>AAPL Price Action</strong>: Apple shares closed at $165.00 on Friday, versus a 52-week trading range of $162.80 to $199.62.</p>
<p><em>Read Next:<a href="https://www.benzinga.com/general/politics/24/04/38305131/elizabeth-warren-says-trump-had-only-2-accomplishments-as-president-huge-difference-between-bide"> Elizabeth Warren Says Trump Had Only 2 Accomplishments As President: &#8216;Huge Difference Between&#8217; Biden, Trump</a></em></p>
<p><em>Photo: Shutterstock</em></p>


Politics

Legal

AAPL

Elizabeth Warren Attacks Apple Smartphone 'Monopoly': 'Green Texts On iPhones, They're Ruining Relationships'

Trading Halt: Halt status updated at 4:55:00 PM ET: Quotation Resumption: News and Resumption Times

Management

AFJK

On April 15, Aimei Health Technology's Juan Fernandez Pascual Tendered His Resignation As CEO, Secretary And A Director; Co Appointed Junheng Xie As CEO, Secretary And A Director

Global

Honda Exec Says Company To Invest 4.2B Reais In Brazil Plant, Focusing On Hybrid-Flex Vehicles

COSM

Cosmos Health Received Nasdaq Notice On Late Filing Of Its Form 10-K; On April 17 Received Notification Letter Stating Co Is No Longer In Compliance With Nasdaq Listing Rule 5250(c)(1); Intends To Resolve Deficiency And Regain Compliance With Nasdaq Listing Rules

BTOG

On Feb 19, Bit Origin Ltd Terminated Employment Of Its CFO, Xia Wang; On April 10, Lucas Wang Resigned As CEO And Chairman Of Board; Current COO, Has Been Appointed CEO, Chairman Of Board And A Director Of Co; Co To Conduct A Search To Replace Xia Wang As Company's CFO

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>ServiceNow</strong>.</p>
<p>Looking at options history for ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) we detected 56 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 64% with bearish.</p>
<p>From the overall spotted trades, 25 are puts, for a total amount of $1,473,153 and 31, calls, for a total amount of $2,469,435.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $300.0 to $1040.0 for ServiceNow over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ServiceNow's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ServiceNow's whale trades within a strike price range from $300.0 to $1040.0 in the last 30 days. </p>
<h3>ServiceNow Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713559550_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$108.8</td>
<td>$106.7</td>
<td>$108.8</td>
<td>$700.00</td>
<td>$598.4K</td>
<td style="text-align: right;">142</td>
<td style="text-align: right;">56</td>
</tr>
<tr>
<td>NOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$37.0</td>
<td>$31.7</td>
<td>$36.5</td>
<td>$500.00</td>
<td>$310.2K</td>
<td style="text-align: right;">35</td>
<td style="text-align: right;">85</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$39.1</td>
<td>$36.7</td>
<td>$39.1</td>
<td>$700.00</td>
<td>$293.2K</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">75</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$32.8</td>
<td>$32.1</td>
<td>$32.1</td>
<td>$720.00</td>
<td>$227.9K</td>
<td style="text-align: right;">75</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$33.0</td>
<td>$31.9</td>
<td>$33.0</td>
<td>$800.00</td>
<td>$132.0K</td>
<td style="text-align: right;">131</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About ServiceNow</h3>
<p>ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.</p>
<h3>Current Position of ServiceNow</h3>
<ul>
<li>Trading volume stands at 1,536,830, with NOW's price down by -2.39%, positioned at $713.91.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 5 days.</li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for ServiceNow, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

This Is What Whales Are Betting On ServiceNow

<p>Financial giants have made a conspicuous bearish move on AstraZeneca. Our analysis of options history for AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) revealed 12 unusual trades.</p>
<p>Delving into the details, we found 16% of traders were bullish, while 83% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $90,336, and 9 were calls, valued at $981,928.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $66.0 and $77.5 for AstraZeneca, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for AstraZeneca's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AstraZeneca's whale activity within a strike price range from $66.0 to $77.5 in the last 30 days. </p>
<h3>AstraZeneca Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713559545_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.06</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$67.50</td>
<td>$594.6K</td>
<td>14.1K</td>
<td>8.2K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.65</td>
<td>$1.54</td>
<td>$1.55</td>
<td>$67.00</td>
<td>$69.4K</td>
<td>2.5K</td>
<td>2.3K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.52</td>
<td>$1.51</td>
<td>$1.51</td>
<td>$67.00</td>
<td>$67.6K</td>
<td>2.5K</td>
<td>1.0K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$1.49</td>
<td>$1.25</td>
<td>$1.49</td>
<td>$67.00</td>
<td>$66.7K</td>
<td>2.5K</td>
<td>24</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.57</td>
<td>$1.48</td>
<td>$1.49</td>
<td>$67.00</td>
<td>$49.6K</td>
<td>2.5K</td>
<td>920</td>
</tr>
</tbody>
</table>
</p>
<h3>About AstraZeneca</h3>
<p>A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.</p>
<p>Following our analysis of the options activities associated with AstraZeneca, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is AstraZeneca Standing Right Now?</h3>
<ul>
<li>With a trading volume of 4,720,283, the price of AZN is up by 0.28%, reaching $68.55.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 6 days from now.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AstraZeneca options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Looking At AstraZeneca's Recent Unusual Options Activity

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Astera Labs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALAB, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for <strong>Astera Labs</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 44% bullish and 55%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $55,500, and 8, calls, for a total amount of $413,781.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $100.0 for Astera Labs during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Astera Labs's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Astera Labs's whale trades within a strike price range from $35.0 to $100.0 in the last 30 days. </p>
<h3>Astera Labs Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713559539_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$21.0</td>
<td>$20.0</td>
<td>$21.0</td>
<td>$50.00</td>
<td>$73.5K</td>
<td style="text-align: right;">43</td>
<td style="text-align: right;">39</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$32.7</td>
<td>$30.9</td>
<td>$32.52</td>
<td>$35.00</td>
<td>$65.0K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$7.7</td>
<td>$7.6</td>
<td>$7.6</td>
<td>$65.00</td>
<td>$63.8K</td>
<td style="text-align: right;">37</td>
<td style="text-align: right;">89</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$6.1</td>
<td>$5.6</td>
<td>$5.9</td>
<td>$65.00</td>
<td>$59.0K</td>
<td style="text-align: right;">37</td>
<td style="text-align: right;">472</td>
</tr>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$11.1</td>
<td>$10.7</td>
<td>$11.1</td>
<td>$75.00</td>
<td>$55.5K</td>
<td style="text-align: right;">425</td>
<td style="text-align: right;">66</td>
</tr>
</tbody>
</table>
</p>
<h3>About Astera Labs</h3>
<p>Astera Labs Inc is a company that offers an Intelligent Connectivity Platform, comprised of Semiconductor-based, high-speed mixed-signal connectivity products that integrate a matrix of microcontrollers and sensors. COSMOS, their software suite which is embedded in its connectivity products and integrated into their customers' systems. The Company delivers critical connectivity performance, enables flexibility and customization, and supports observability and predictive analytics. This approach addresses the data, network, and memory bottlenecks, scalability, and other infrastructure requirements of hyperscalers and system original equipment manufacturers.</p>
<p>Having examined the options trading patterns of Astera Labs, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Astera Labs</h3>
<ul>
<li>Trading volume stands at 3,996,863, with ALAB's price down by -10.18%, positioned at $63.7.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 14 days.</li>
</ul>
<h3>What Analysts Are Saying About Astera Labs</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $88.0.</p>
<ul>
<li>Reflecting concerns, an analyst from Evercore ISI Group lowers its rating to Outperform with a new price target of $100.</li>
<li>An analyst from Barclays downgraded its action to Overweight with a price target of $85. </li>
<li>Reflecting concerns, an analyst from Roth MKM lowers its rating to Buy with a new price target of $85.</li>
<li>In a cautious move, an analyst from JP Morgan downgraded its rating to Overweight, setting a price target of $85. </li>
<li>Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $85.</li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Astera Labs, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


ALAB

Decoding Astera Labs's Options Activity: What's the Big Picture?

LPTX

Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024

Offerings

KZIA

Kazia Therapeutics Ltd Entered Into Purchase Agreement With Alumni Capital LP; Pursuant To Purchase Agreement, May Sell To Alumni Capital Up To $15M Of American Depositary Shares From Time To Time

MNTS

Momentus Inc Receives Nasdaq Deficiency Notification Regarding Delayed Form 10-K

<p>Gulf Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GURE#NASDAQ">GURE</a>) ("Gulf Resources" or the "Company"), a leading manufacturer of bromine, crude salt and specialty chemical products in China, today announced that it received a notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "2023 Form 10-K"), with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires the timely filing of all required periodic reports with the SEC.<br /><br />&nbsp;</p>
<p>The Notice has no immediate effect on the listing of the Company's common stock on Nasdaq. Under the Nasdaq rules, the Company has 60 calendar days, or until June 17, 2024, to file the 2023 Form 10-K or to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. If the Company submits a plan to Nasdaq and Nasdaq accepts the plan, Nasdaq can grant an exception of up to 180 calendar days from the filing's due date, or until October 14, 2024, to regain compliance. If the Company fails to timely regain compliance with Nasdaq Listing Rule 5250(c)(1), the Company's common stock will be subject to delisting from Nasdaq.</p>
<p>The Company continues to work diligently to complete the 2023 Form 10-K and currently intends to file the 2023 Form 10-K by no later than June 10, 2024.</p>
<p>This announcement is made in compliance with the Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a notification of deficiency.</p>


GURE

Gulf Resources Announces Receipt Of Nasdaq Non-Compliance Notice Notifying The Company That Due To The Co's Failure To Timely File Its Annual Report On Form 10-K For The Fiscal Year Ended December 31, 2023

<p>Lifecore Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) (the "Company") announced today that, on April 15, 2024, the Company received a notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended February 25, 2024 (the "Q3 Form 10-Q") and its continued delay in filing its Quarterly Report on Form 10-Q for the quarterly periods ended August 27, 2023 and November 29, 2023 (the "Q1 Form 10-Q" and "Q2 Form 10-Q," respectively, and together with the Q3 Form 10-Q, the "Filings") with the Securities and Exchange Commission (the "SEC"), the Company continues not to be in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), and that the Nasdaq Hearings Panel would consider the delinquency in the filing of the Q3 Form 10-Q in rendering its determination regarding the Company's continued listing on Nasdaq Global Select Market.<br /><br />&nbsp;</p>
<p>The Notice has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Global Select Market. As previously disclosed, Nasdaq had previously granted the Company until February 12, 2024 to regain compliance with the Listing Rule, and, on February 13, 2024, the Company received the Staff Delisting Determination notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company's securities from Nasdaq as a result of the Company not being in compliance with the Listing Rule. The Company appealed the Staff Delisting Determination, and, on April 16, 2024, the Company appeared for the hearing in which the Company requested a further stay of any suspension or delisting action to enable the Company to regain compliance with the Listing Rule. The Nasdaq Hearings Panel has not yet issued its decision, although the Company anticipates that a decision will be forthcoming.</p>
<p>The Company continues to work diligently to complete the Filings and intends to file the Filings as promptly as possible to regain compliance under the Listing Rule. However, there can be no assurance that such periodic reports will be filed before the expiration of any stay granted by Nasdaq, or that the Nasdaq Hearing Panel will grant the Company's request for a further stay of any suspension or delisting action</p>
<p>This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.</p>


LFCR

Lifecore Biomedical, Inc. Receives Notice From Nasdaq Regarding Delayed Quarterly Report For The Fiscal Quarter Ended February 25, 2024 And Its Continued Delay In Filing Its Quarterly Report On Form 10-Q For The Quarterly Periods Ended August 27, 2023 And November 29, 2023

<p>Odyssey Marine Exploration, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>), a global subsea mineral exploration and validation company, reported that on April 17, 2024, Odyssey received a notice from Nasdaq Regulation that Odyssey is not in compliance with Nasdaq Rule 5250(c)(1) because it had not yet filed its Form 10-K for the period ended December 31, 2023 (the "Form 10-K") with the Securities and Exchange Commission (SEC). Odyssey plans to regain compliance with Nasdaq Rule 5250(c)(1) by filing the Form 10-K with the SEC, which it expects to do as soon as practicable.</p>


OMEX

Odyssey Marine Exploration Addresses NASDAQ Compliance Matters; Plans To Regain Compliance With Nasdaq Rule 5250(c)(1) By Filing The Form 10-K With The SEC, Which It Expects To Do As Soon As Practicable

<p>Intelligent Living Application Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) ("Intelligent Living" or the "Company"), a premium lockset manufacturer in Hong Kong, announced today that, on April 17, 2024, the Company received a written notification from the NASDAQ Stock Market Listing Qualifications Staff (the "Staff") indicating that the Company has been granted an additional 180 calendar day period or until October 14, 2024, to regain compliance with the $1.00 minimum closing bid price requirement for continued listing on the NASDAQ Capital Market pursuant to NASDAQ Listing Rule (the "Minimum Bid Price Requirement").</p>
<p>NASDAQ's determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the NASDAQ Capital Market, with the exception of the bid price requirement, and the Company's written notice to NASDAQ of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this additional time period the closing bid price of the Company's security is at least $1.00 per share for a minimum of 10 consecutive business days, NASDAQ will provide written confirmation of compliance and this matter will be closed. If compliance cannot be demonstrated by October 14, 2024, Staff will provide written notification that the Company's securities will be delisted. At that time, the Company may appeal the Staff's determination to a Hearings Panel (the "Panel") of NASDAQ.</p>
<p>This notification from Nasdaq has no immediate effect on the listing or trading of the Company's ordinary shares, which will continue to trade on the Nasdaq Capital Market under the symbol "ILAG".&nbsp; The Company will monitor the closing bid price of its ordinary shares and will consider various options to regain compliance before October 14, 2024.</p>


ILAG

Intelligent Living Application Group Inc. Granted Extension Indicating That The Co Has Been Granted An Additional 180 Day Or Until October 14, 2024, To Regain Compliance With The $1.00 Minimum Closing Bid Price Requirement To Meet Nasdaq Minimum Bid Price Requirement

In a report released today, David Li from Bank of America Securities reiterated a Buy rating on Zai Lab (ZLAB – Research Report), with a price targ...

Buy Rating Affirmed for Zai Lab Amid Strong Sales Performance and Positive Development Outlook

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p></p>



<p>Small cap stocks like those discussed below tend to receive much less attention than their large cap competitors. Shares, which boast a market capitalization between $250 million and $2 billion, remain relatively small. The largest stocks including <strong>Nvidia</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nvda-stock-quote/"><strong>NVDA</strong></a></span>) and <strong>Microsoft</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/msft-stock-quote/"><strong>MSFT</strong></a></span>) are valued into the trillions. It&rsquo;s no surprise then that they receive the lion&rsquo;s share of investor attention and capital.&nbsp;</p>



<p>As a result, there are a lot of deals to be had among small-cap stocks. Investors don&rsquo;t hear about these names on a day-to-day basis and the media is certainly less likely to cover them. That doesn&rsquo;t mean that investors should ignore them or that the firms behind their stocks are insignificant.</p>



<p>The same successes in an innovation that can be found in the biggest firms is also happening in small cap companies as well. Let&rsquo;s take a look at seven such shares that are expected to double in price by 2025.&nbsp;</p>



<h2>Zai Lab Limited (ZLAB)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div><p><strong>Zai Lab Limited</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/zlab-stock-quote/"><strong>ZLAB</strong></a></span>) is one of two biopharmaceutical stocks discussed in this article. investors are well aware that this particular sector has a history of producing outsized gains. It requires vast fortunes to develop successful therapeutics but many failures result. The result is that the sector produces many busts but those that succeed rise dramatically.</p>



<p>Zai Lab Limited isn&rsquo;t one of those firms that is chasing its initial success. Instead, the firm is relatively well established through a series of revenue streams. Yet, at the same time, the company does have a growth stream. The company <a href="https://www.businesswire.com/news/home/20240227802106/en/Zai-Lab-Announces-Full-Year-2023-Financial-Results-and-Recent-Corporate-Updates/">launched VYGART in September 2023 and it has already seen $10 million in sales</a>.&nbsp; The drug treats a rare neuromuscular condition called myasthenia gravis.&nbsp;</p>



<p>Otherwise, the company has a stable of other strong therapeutics that are growing rapidly. The result is that in 2023 overall sales increased by 25%, rising to $266.7 million.&nbsp; That has analysts excited and they believe that at the <a href="https://stockanalysis.com/stocks/zlab/forecast/">consensus level its price can rise above $64</a>, well above its current $20 price.</p>



<h2>Tandem Diabetes Care (TNDM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/07/biopharma-1600-300x169.jpg" alt="a scientist with protective equipment and microscope in a lab, OBSV stock"><div>Source: luchschenF / Shutterstock.com</div></div><p><strong>Tandem Diabetes Care</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tndm-stock-quote/"><strong>TNDM</strong></a></span>) is not as clear a winner as Zai Labs Limited but there are several things to like about the firm and its stock. From a fundamental perspective Tandem Diabetes Care is not a firm that particularly stands out. Instead, its growth has been relatively flat and its losses have increased. It also has<a href="https://www.businesswire.com/news/home/20240221234957/en/Tandem-Diabetes-Care-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-2024-Financial-Guidance/"> enough liquidity to continue to operate for a few years into the future without any problems</a>.</p>



<p>It isn&rsquo;t perfect but the company does have a few catalysts that make it potentially worthwhile for investors. Perhaps most importantly, the <a href="https://stockanalysis.com/stocks/tndm/forecast/">high analyst price is more than double</a> its current $28 share price.</p>



<p>Additionally, the company recently <a href="https://www.businesswire.com/news/home/20240213214991/en/Tandem-Diabetes-Care-Launches-Tandem-Mobi-the-World%E2%80%99s-Smallest-Durable-Automated-Insulin-Delivery-System/">launched the world&rsquo;s smallest automated insulin delivery system</a> called Mobi. The pump is indicated for those patients with type 1 diabetes. That&rsquo;s important to note because type 2 diabetes is undergoing a shift with the introduction of drugs such as Wegovy and Zepbound. The point being that type 1 diabetes is a genetically driven disease that is uncontrollable through diet and exercise alone. Thus, demand for the Mobi delivery system is likely to be strong while also being less subject to external forces.</p>



<h2>HighPeak Energy (HPK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/04/oil-stocks1600-300x169.png" alt="Oil. 3D Illustration. Oil stocks are up."><div>Source: Pavel Ignatov / Shutterstock.com</div></div><p><strong>HighPeak Energy</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/hpk-stock-quote/"><strong>HPK</strong></a></span>) is one of many independent oil exploration and production firms based in the United States. Those firms and their stocks look increasingly attractive as the geopolitical energy&nbsp;climate grows increasingly complex in 2024.</p>



<p>In short, U.S. oil assets are in position to become very valuable should tensions escalate globally and within the Middle East in particular. That&rsquo;s part of the reason that analysts believe<a href="https://stockanalysis.com/stocks/hpk/forecast/"> shares could rise as high as $34</a> in the next 12 months. That would more than represent a doubling above its current $15 share price.&nbsp;</p>



<p>Another reason that many are positive about the future of high peak energy is that the firm is surpassing milestones. In 2023, the company <a href="https://www.globenewswire.com/news-release/2024/03/06/2841764/0/en/HighPeak-Energy-Inc-Announces-Fourth-Quarter-and-Yearend-2023-Financial-and-Operating-Results-and-Provides-2024-Guidance.html">surpassed $1 billion in revenues for the first time ever</a>. That led to free cash flow of nearly $34 million over the period.</p>



<p>The company&rsquo;s proven reserves also increased by 25% between the end of 2022 and the end of 2023. Thus, should prices rise on geopolitical tensions, its U.S. based reserves would become that much more valuable.</p>



<h2>Crescent Energy Corporation (CRGY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/oil1600-300x169.png" alt="In the field, the oil pump in the evening, the evening silhouette of the pumping unit, the silhouette of the oil pump. Oil stocks and energy stocks"><div>Source: zhengzaishuru / Shutterstock.com</div></div><p><strong>Crescent Energy Corporation</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/crgy-stock-quote/"><strong>CRGY</strong></a></span>) stock is interesting for many of the same reasons that HighPeak Energy, immediately above, is interesting. Both firms operate in the oil and gas E&amp;P sector. It means they explore and produce oil and natural gas assets which are subject to the inherent volatility of commodity markets.</p>



<p>In short, it&rsquo;s the same story here: Analysts see <a href="https://stockanalysis.com/stocks/crgy/forecast/">real potential for the stock to double in the next 12 months</a>. The company&rsquo;s assets are located within North America meaning they have the potential to become much more valuable should other global strategic resources rise in price. That will or will not happen depending upon geopolitical forces which are inherently difficult to predict.</p>



<p>While those catalysts remain difficult to predict, there are also fundamental reasons to believe in Crescent Energy Corporation. <a href="https://irpages2.eqs.com/download/companies/270166a/Press%20Releases/Crescent%20Energy%20Reports%20Fourth%20Quarter%20and%20Full%20Year%202023%20Results.pdf">4th quarter oil revenues were up </a>suggesting that the strategic importance of U.S.-based resources is increasing. It&rsquo;s also important to note that oil revenues make up the bulk of Crescent Energy Corporation&rsquo;s revenues.</p>



<h2>Schrodinger (SDGR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/03/biotech-stocks-2-300x169.jpg" alt="A close-up concept image of a tiny glass vial with a strand of DNA in it. best biotech stocks"><div>Source: Shutterstock</div></div><p><strong>Schrodinger</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/sdgr-stock-quote/"><strong>SDGR</strong></a></span>) is part biotech stock and part AI stock. The company continues to develop a physics-based computational platform that has utility in the drug discovery and development sector.&nbsp;</p>



<p>In order to develop a therapeutic, biotechnology firms first have to identify molecules that have the potential to treat a target disease. It&rsquo;s a painstaking process that is becoming easier through the use of computers, machine learning, and artificial intelligence.</p>



<p>Schrodinger has emerged as a leading name in that space. The company essentially does two things. One, it licenses its technology to firms wishing to discover molecules with treatment potential. Two, the company is also currently building a portfolio of clinical and preclinical programs.</p>



<p>It&rsquo;s easy then to see why analysts believe its shares could grow rapidly: It has an in-demand product that it can sell to firms that lack its technological know-how. Further, Schrodinger has the potential to produce a blockbuster drug of its own. Perhaps most importantly, the company <a href="https://www.businesswire.com/news/home/20240228496610/en/Schr%C3%B6dinger-Reports-Strong-Fourth-Quarter-and-Full-Year-2023-Financial-Results/">grew its revenues by more than 30%</a> during the fourth quarter.</p>



<h2>Bumble (BMBL)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/02/bmbl1600-300x169.jpg" alt="BUMBLE (BMBL) app on a smartphone"><div>Source: XanderSt / Shutterstock.com</div></div><p>Dating app<strong> Bumble</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/bmbl-stock-quote/"><strong>BMBL</strong></a></span>) isn&rsquo;t doing very well at the moment. That&rsquo;s a big part of the reason that investors should consider buying the stock now.</p>



<p>Essentially, Bumble is doing better now than it did a year ago but is still falling short of Wall Street&rsquo;s expectations. It forced the company to take the drastic step of <a href="https://techcrunch.com/2024/02/27/bumble-cuts-350-employees-as-dating-apps-face-a-reckoning/">reducing its workforce by 30%</a>. That decision was made with the intention of increasing earnings while the company also undertakes an app overhaul.&nbsp;</p>



<p>The company is attempting to appeal to a younger audience akin to that of its main rival, <strong>Match</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/mtch-stock-quote/"><strong>MTCH</strong></a></span>). If the company can do that, it will obviously help it to increase its earnings. That, combined with the layoffs, could foreseeably spike earnings dramatically in the coming quarters. That said, Bumble is not expected to enact a rapid turnaround and the first quarter is expected to continue to be muted.</p>



<h2>Alphatec Holdings (ATEC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/02/atec-stock-1-300x169.jpg" alt="A magnifying glass zooms in on the Alphatec Holdings, Inc. (ATEC) logo"><div>Source: Pavel Kapysh / Shutterstock.com</div></div><p><strong>Alphatec Holdings</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/atec-stock-quote/"><strong>ATEC</strong></a></span>) is a pretty humdrum firm as far as its operations goes. It develops products and technologies used in the surgical treatment of spinal disorders. However, it&rsquo;s also a fundamentally strong firm which is why its stock is so well regarded at the moment.</p>



<p>How well regarded is it? Well, analysts rate it a strong buy overall and its<a href="https://stockanalysis.com/stocks/atec/forecast/"> $13 shares have the potential to rise as high as $32</a>.</p>



<p>The reason to believe that those analysts are right lies in its recent earnings report. That report showed that revenues increased by 37% in 2023, reaching $482 million. A big part of that growth must be due to the fact that the company trained over 500 surgeons in 2023. That amounted to a 27% increase in the number of surgeon users between 2022 and 2023. The greater the number of surgeons with familiarity with its products, the easier it will be for Alphatec Holdings to sell its products and services.</p>



<p></p>



<p><em>On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em> Publishing Guidelines</em></a><em>.</em></p>
<div><p>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/03/shhh-7-small-cap-stocks-that-can-double-by-2025/">Shhh! 7 Small-Cap Stocks That Can Double by 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Shhh! 7 Small-Cap Stocks That Can Double by 2025

Novocure climbs after late-stage win for lung cancer therapy

Zai Lab reports Krazati lung cancer study meets primary endpoint

ProfoundBio will be acquired by Copenhagen's Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab's drug portfolio, including three ProfoundBio clinical stage ADC candidates for solid tumors.

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Inozyme Pharma (INZY – Research Report), Zai Lab (ZLAB – Research...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)

ClearBridge International Growth ADR Strategy Q1 2024 Commentary

A Risky Bet: Zai Lab's Uncertain Future

ClearBridge International Growth ACWI Ex-US Strategy Q1 2024 Commentary

Zai Lab files automatic ordinary shares offering

AAGIY

AAIGF

AMADF

AMADY

ASML

ASMLF

ASND

ATEC

BMBL

BNTX

CACG

CFCV

CHSYF

CMSQF

CMSQY

CRGY

DAIUF

EDNMF

EDNMY

EPSN

EQBBF

GMAB

GVDNY

HKXCF

HKXCY

IBDRY

IBDSF

IDEXF

IDEXY

IDXX

INCY

INFR

INZY

IVBXF

JHIUF

LRGE

LVMHF

LVMUY

MNDY

MSFT

MTCH

NONOF

NSRGF

NSRGY

NVCR

NVDA

PGPEF

PUBGY

RACE

SAFRF

SAFRY

SAPGF

SBGSF

SBGSY

SDGR

SDVKF

SDVKY

SFTBF

SFTBY

SMMYY

SNEJF

SONY

SSDOF

SSDOY

STMNF

TNDM

TOELF

TOELY

TSMWF

TSYHF

TSYHY

YLDE

ZLDPF

Press Releases

Qiming Venture Partners Becomes a UN PRI Signatory

Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates

Zai Lab Announces Participation in March Investor Conference

Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)

Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...

Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs

Zai Lab Statement on Executive Management Team's Agreement on Share Activities

Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024